Treatment News : Treat Hep C if HIV-Coinfected Have Advanced Fibrosis

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » August 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


August 26, 2013

Treat Hep C if HIV-Coinfected Have Advanced Fibrosis

Those coinfected with hepatitis C virus (HCV) and HIV who have advanced fibrosis should receive treatment for hep C, because of the risk for developing liver decompensation, reports. Publishing their findings in Clinical Infectious Diseases, investigators conducted a retrospective cohort study of 892 participants coinfected with hep C and HIV. The participants all had advanced fibrosis and were in care between November 1990 and June 2012. They had either never received hep C treatment or had not responded to previous treatment. To diagnose their liver fibrosis, the researchers gave them a liver biopsy or a liver stiffness measurement.

Out of the 317 participants who received a biopsy, 40 developed liver decompensation—a more advanced stage of liver disease—for a rate of 2.3 decompensations per 100 person-years. There was a 10 percent risk of developing liver decompensation within five years. Twelve participants who had stage 3 fibrosis at the beginning of the study developed decompensation, for an incidence  of 1.4 per 100 person-years.  Twenty-eight participants who had cirrhosis at the opening of the study developed decompensation, yielding an incidence of 3.1 per 100 person years.

Out of the 575 participants who received a liver stiffness measurement, 53 developed decompensation, for a rate of 3.98 decompensations per 100 person-years. The risk of developing liver decompensation within five years was 23 percent.

The researchers concluded that care providers should more proactively prescribe hep C therapy for those with advanced fibrosis.

To read the story, click here.

To read the study abstract, click here.

Search: Hepatitis C virus, HCV, hep C, advanced fibrosis, coinfected,, Clinical Infectious Diseases, HIV, liver decompensation.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Hide comments

Previous Comments:


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.